Atai Life Sciences announced positive results from Beckley Psytech's Phase 2a study of BPL-003, an adjunctive treatment for patients with treatment-resistant depression (TRD) who are already on ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback